Fighting autoinflammation in FIRES: The role of interleukins and early immunomodulation

•Early recognition of FIRES is key to provide possibly disease-modifying therapies.•Serum IL-1RA dosage may help to support treatment intensification.•Anakinra and ketogenic diet represent encouraging immunomodulatory strategies.•Their effect may be synergistic but further evidence in support is nee...

Full description

Saved in:
Bibliographic Details
Published inEpilepsy & behavior reports Vol. 18; p. 100531
Main Authors Perulli, Marco, Cicala, Gianpaolo, Turrini, Ida, Musto, Elisa, Quintiliani, Michela, Gambardella, Maria Luigia, Pulitanò, Silvia Maria, Bompard, Sarah, Staccioli, Susanna, Carmillo, Laura, Di Sante, Gabriele, Ria, Francesco, Veredice, Chiara, Contaldo, Ilaria, Battaglia, Domenica
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2022
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•Early recognition of FIRES is key to provide possibly disease-modifying therapies.•Serum IL-1RA dosage may help to support treatment intensification.•Anakinra and ketogenic diet represent encouraging immunomodulatory strategies.•Their effect may be synergistic but further evidence in support is needed.•Structured neuropsychological testing is a relevant outcome measure of treatments. Febrile infection-related epilepsy syndrome (FIRES) is a challenging condition with unfavorable outcome in most cases. Preliminary evidence suggests that some interleukins, in particular IL-1 Receptor Antagonist (IL-1RA), could be elevated due to a functional deficiency of anti-inflammatory pathways. Therefore, treatment strategies acting on innate immunity could represent a targeted treatment. We describe the case of an 11-year-old child with super-refractory status epilepticus (SE), lasting more than two months. After being treated aggressively with antiseizure medications, anesthetics and empiric treatment for autoimmune encephalitis without success, she responded to anakinra and ketogenic diet. Escalation of the therapy was supported by the finding of a very high serum level of IL-1RA. This immunomodulatory approach allowed to discharge the child from intensive care 48 days after the SE onset. After more than one year follow-up the patient has moderate intellectual disability but with good language skills; she is seizure free and without motor deficits. This case suggests that serum IL-1RA serum levels may help to support treatment escalation. Moreover, anakinra and ketogenic diet represent encouraging immunomodulatory strategies which deserve further studies and could potentially have a synergistic effect. Finally, structured neuropsychological testing is an important outcome measure that will help to define the effectiveness of different treatment strategies.
ISSN:2589-9864
2589-9864
DOI:10.1016/j.ebr.2022.100531